Literature DB >> 24683208

Effects of milrinone and olprinone on hypercapnic depression of diaphragmatic contractility in pentobarbital-anesthetized dogs.

Yoshitaka Fujii1, Aki Uemura2.   

Abstract

UNLABELLED: Abstract.
BACKGROUND: Hypercapnia is associated with diaphragm muscle dysfunction that is a reduction of diaphragmatic force generated for stable electric myographic activity.
OBJECTIVE: The purpose of this study was to test the effects of milrinone and olprinone on decreased diaphragmatic contractility induced by hypercapnia in pentobarbital-anesthetized dogs.
METHODS: This experimental study was conducted at the Department of Anesthesiology, University of Tsukuba, Institute of Clinical Medicine, Tsukuba, Japan. Hypercapnia (partial pressure of carbon dioxide [CO2] in arterial blood 80-90 mm Hg) was induced by adding 10% CO2 to the inspired gas. When hypercapnia was established, group 1 received no study drug, group 2 was infused with milrinone (50 g/kg initial dose plus 0.5 g/kg · min(-1) thereafter), and group 3 was infused with olprinone (10 g/kg initial dose plus 0.3 g/kg · min(-1) thereafter). Diaphragmatic contractility was assessed by transdiaphragmatic pressure (Pdi).
RESULTS: Twenty-four, healthy, adult mongrel dogs were used in the study; 8 dogs were assigned to each treatment group. In the presence of hypercapnia, in each group, Pdi (mean [SD], cm-H2O) at low-frequency (20 Hz) and highfrequency (100 Hz) stimulation significantly decreased from baseline (group 1: 20 Hz, 15.1 [2.4] vs 13.3 [2.7]; 100 Hz, 23.1 [2.7] vs 20.6 [2.5], both, P = 0.001; group 2: 20 Hz, 15.2 [2.0] vs 13.2 [2.5]; 100 Hz, 23.0 [2.5] vs 20.5 [2.5], both, P = 0.001; group 3: 20 Hz, 15.0 [2.2] vs 13.2 [2.1]; 100 Hz, 23.0 [2.5] vs 20.5 [2.7], both, P = 0.001). In group 1, the change in Pdi with regard to each stimulus was not significant when compared with the hypercapnia-induced values. In groups 2 and 3, during study-drug administration, Pdi increased significantly in response to both stimuli compared with hypercapnia-induced values (group 2: 20 Hz, 13.2 [2.5] vs 18.8 [2.2]; 100 Hz, 20.5 [2.5] vs 27.7 [2.3], both, P = 0.001; group 3: 20 Hz, 13.2 [2.1] vs 22.3 [3.5]; 100 Hz, 20.5 [2.7] vs 30.8 [2.2], both, P = 0.001). The increase in Pdi with both stimuli was significantly greater in group 3 than in group 2 (20 Hz, 22.3 [3.5] vs 18.8 [2.2], P = 0.035; 100 Hz, 30.8 [2.2] vs 27.7 [2.3], P = 0.046).
CONCLUSIONS: The results of this experimental study of the effects of milrinone and olprinone on hypercapnic depression of diaphragmatic contractility in these pentobarbital-anesthetized dogs suggest that olprinone and milrinone significantly improved diaphragm muscle dysfunction induced by hypercapnia. The effects of olprinone were significantly greater than those of milrinone. Further studies are needed to determine the optimal dose of the study drugs.

Entities:  

Keywords:  contractility; diaphragm; hypercapnia; milrinone; muscle; olprinone

Year:  2007        PMID: 24683208      PMCID: PMC3967368          DOI: 10.1016/j.curtheres.2007.05.001

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  16 in total

1.  Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs.

Authors:  Y Fujii; H Toyooka
Journal:  Can J Anaesth       Date:  2000-12       Impact factor: 5.063

2.  Effect of acute moderate changes in PaCO2 on global hemodynamics and gastric perfusion.

Authors:  A Mas; P Saura; D Joseph; L Blanch; F Baigorri; A Artigas; R Fernández
Journal:  Crit Care Med       Date:  2000-02       Impact factor: 7.598

3.  Effect of sevoflurane on diaphragmatic contractility in dogs.

Authors:  T Ide; T Kochi; S Isono; T Mizuguchi
Journal:  Anesth Analg       Date:  1992-05       Impact factor: 5.108

4.  Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.

Authors:  H Ohhara; T Ogawa; M Takeda; H Katoh; Y Daiku; T Igarashi
Journal:  Arzneimittelforschung       Date:  1989-01

5.  Editorial: the early "pump" failure of the ischemic heart.

Authors:  A M Katz; H H Hecht
Journal:  Am J Med       Date:  1969-10       Impact factor: 4.965

6.  Respiratory muscle strength in chronic obstructive pulmonary disease.

Authors:  D F Rochester; N M Braun; N S Arora
Journal:  Am Rev Respir Dis       Date:  1979-02

7.  Assessment of responsiveness to carbon dioxide in patients with chronic airways obstruction by rate of isometric inspiratory pressure development.

Authors:  A W Matthews; J B Howell
Journal:  Clin Sci Mol Med       Date:  1976-03

8.  Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.

Authors:  T Ogawa; H Ohhara; H Tsunoda; J Kuroki; T Shoji
Journal:  Arzneimittelforschung       Date:  1989-01

9.  Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

Authors:  E J Eichhorn; M A Konstam; D S Weiland; D J Roberts; T T Martin; N B Stransky; D N Salem
Journal:  Am J Cardiol       Date:  1987-12-01       Impact factor: 2.778

10.  The influence of hydrogen ion concentration on calcium binding and release by skeletal muscle sarcoplasmic reticulum.

Authors:  Y Nakamaru; A Schwartz
Journal:  J Gen Physiol       Date:  1972-01       Impact factor: 4.086

View more
  2 in total

1.  Effects of dibutyryl cyclic adenosine monophosphate on hypercapnic depression of diaphragmatic contractility in pentobarbital-anesthetized dogs.

Authors:  Yoshitaka Fujii; Aki Uemura
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

2.  Dose-related effects of olprinone on hypercapnia-Induced impairment of diaphragmatic contractility in pentobarbital-anesthetized dogs.

Authors:  Yoshitaka Fujii; Aki Uemura
Journal:  Curr Ther Res Clin Exp       Date:  2008-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.